Marshall Protocol DVD Set 

Researching the Marshall Protocol   
is an essential part of your   
Lyme Disease education!   

    > 2005 Chicago Conference: "Recovering from Chronic Disease"
    > 2005 Hartford Conference: "30th Anniversary of Lyme"

Exclusively Offered by www.Lymebook.com!

$45

4-DVD Set:

The Marshall Protocol: a Breakthrough in the Treatment of Cell-Wall-Deficient Bacteria

The Marshall protocol is not just important, but critical in Lyme disease recovery.  It addresses a part of the Lyme disease complex that no other treatment, protocol, diet, or supplement can even come close to touching: infection with cell-wall-deficient bacteria.

Borrelia burgdorferi, the causative bacteria in Lyme disease, comes in three forms: spirochete, cyst, and cell-wall-deficient.  Spirochetes are successfully killed by rife machines (see www.lymebook.com).  Cysts can be killed by certain types of antibiotics (including 5-nitromidizoles and hydroxychloroquine).  Cysts can also be exposed and killed by rife therapy with proper treatment timing and planning.  However, until the Marshall Protocol, there was not an effective treatment for cell-wall-deficient bacteria.

Conventionally, doctors have tried to use certain types of antibiotics to kill cell-wall-deficient bacteria.  Top choices include protein synthesis inhibitors such as the macrolides (Zithromax and Biaxin), the ketolides (Ketek), and the tetracyclines (tetracycline, doxycycline, and minocycline).  Unfortunately, these antibiotics have been ineffective at worst and only moderately effective at best.

Trevor G Marshall, PhD:  A Biography Trevor's first teaching post was at the University of Technology in Lae, Papua New Guinea, during 1974. He taught at Curtin University, in Western Australia, during the rest of the 70's. Following up on his Masters degree in 1978, he commenced PhD studies at the University of Western Australia, home to Barry Marshall (no relation) (of Helicobacter Pylori fame). Clinical studies were with Tim Welborn and Ted Keogh at the Sir Charles Gairdner Hospital in Western Australia and Mike Albisser's group at the Hospital for Sick Children in Toronto.  In 1982 he moved to the USA, and now lives in California. His PhD thesis "Mathematical Modelling of the Insulin Glucose Homeostasis in Diabetic and Healthy Individuals" was accepted in 1985. For most of the succeeding decades he was CEO of YARC Systems, specializing in high-tech Internet Publishing. Over the last few years Trevor has been defining the biochemical roles of the steroid hormones Angiotensin II and 1,25-dihydroxyvitamin-D in immune disease. In 2002 he published a complete etiological description for Sarcoid Inflammation, and his current interest is in understanding how this same hormonal/bacterial pathogenesis might drive other Rheumatic and Cardiac diseases. Trevor Marshall founded the Autoimmunity Research Foundation.

Since cell-wall-deficient bacteria cause the most severe symptoms and worst disease manifestations of the three bacterial forms, discovering a way to kill them is no trivial pursuit.  In fact, cell-wall-deficient bacteria are responsible for most of the devastating and debilitating aspects of chronic Lyme disease.  So, killing these bacteria should theoretically result in tremendous improvement in symptoms.  Which is exactly what happens with the Marshall protocol: Lyme sufferers using it have noticed accelerated recovery, leaps and bounds of symptom improvement, and even permanent progress that endures after the protocol is discontinued.

Many diseases, one treatment

Additionally, because evidence suggests that cell-wall-deficient bacteria are the root cause of numerous other allegedly incurable diseases, a treatment that successfully kills this bacteria should greatly benefit sufferers of many different types of chronic illnesses, not just Lyme disease.  The Marshall protocol has produced astounding results.  Hundreds of people, with diseases ranging from multiple sclerosis and fibromyalgia, to obsessive-compulsive disorder and depression, have gained significant improvement, and in some cases recovery, via the Marshall protocol.  These results suggest that the Marshall protocol is one of the most significant breakthroughs in the past 100 years of infectious disease medicine.

Where did the Marshall protocol come from?

The Marshall protocol gets its name from Dr. Trevor Marshall, Ph.D., who suffered for decades from sarcoidosis, a disease that shares a common root cause with Lyme disease: cell-wall-deficient bacteria.  The difference between sarcoidosis and Lyme disease is that sarcoidosis is often fatal.  Lyme disease, while debilitating, is typically not fatal.  Therefore, breakthroughs in sarcoidosis treatment are not only more urgent but also easier to quantify - the measuring stick for sarcoidosis therapy is not just how much better someone feels, but whether or not they die.  Dr. Marshall is alive and well today, completely recovered from sarcoidosis, due to his use of the Marshall protocol, which he invented.  In recent times, a large number of Lyme disease sufferers have began using the Marshall protocol, with similarly amazing results. To learn more about the Marshall protocol, read this 4-page excerpt from Lyme Disease and Rife Machines.

About the DVD set

This DVD set is exclusively offered by lymebook.com.  It was assembled for lymebook.com by the Autoimmunity Research Foundation and includes video recordings from two different conferences of particular interest to Lyme disease sufferers.

Conference #1: 30th Anniversary of Lyme
Hartford, Connecticut, May 7, 2005

DVD 1: "How Borrelia evades the immune system, and how we help the immune system kill this Th1 bacterium"

Conference #2: Recovering from Chronic Disease
Chicago, Illinois, March 12-13, 2005

DVD 2: "Plenary Session: Dr. Marshall, Dr. Mattman, Dr. Wright, Dr. Jason, Dr. Whitley, Dr. Kiley"

DVD 3: "Patients' Tutorial" 

DVD 4: "Panel Sessions" 

Conference Speakers:
F
James P Kiley, PhD, is the Director of the Division of Lung Diseases, NHLBI, National Institutes of Health (NIH). He was previously Director of the National Center on Sleep Disorders Research at the NHLBI. Dr Kiley received an award for having heightened public awareness of sleep disorders. He has published numerous scientific papers in the fields of Respiratory and Cardiovascular disease.		Leonard Jason, PhD, is a prolific CFS/CFIDS/ME researcher. For more than a decade, Jason and his team at the Center for Community Research of DePaul University, have worked to define the scope and impact of CFS worldwide. He was Principal Investigator of a community-based epidemiologic study of CFS, and co-wrote the "Handbook of Chronic Fatigue Syndrome."
Lida H Mattman, PhD, has spent seven decades studying the different forms that bacteria can take, publishing the textbook on Stealth Pathogens, "Cell Wall Deficient Forms." Her contributions to medical science can be summarized best by noting that in 1998 she was nominated for the highest honor attainable in her profession: The Nobel Prize in Medicine.		Janet Whitley, PhD, a Regulatory Review Scientist with the Office of Orphan Products Development (OOPD) at the FDA, administers the provisions of the Orphan Drug Act which provide incentives for the development of medical products for serious and life-threatening conditions. She has received numerous awards including the FDA Outstanding Scientific Achievement Award, FDA Leveraging/Collaboration Award, and the FDA Quality of Worklife Award.
Andrew Wright, MD, is researching the bacteriological causes of 'Fatigue Spectrum Disorders,' especially CFS/ME and Fibromyalgia, and is using innovative High Resolution Dark-field and Phase-Contrast Microscopy to identify and photograph the pathogens in patients' blood. He is also pursuing joint projects with the Microbiological Units of several UK Universities.		Trevor G Marshall, PhD, has researched such diverse fields as Cryptorchidism, Male and Female Infertility, and subcutaneous Insulin infusion. Most recently he has deduced and published a bacterial pathogenesis for the Th1 diseases, including chronic-Lyme, CFS and Sarcoidosis. From this pathogenesis, a treatment called the 'Marshall Protocol' has been derived, and is being implemented by physicians worldwide.
Meg Mangin, RN, graduated from Milwaukee School of Nursing in 1971. She has held staff nurse positions in coronary/intensive care, and for the past thirteen years has provided skilled home-nursing services in a variety of medical specialties. Meg headed the Wisconsin LaLeche League for five years. She is currently serving on an NIH Data, Safety and Monitoring Board.
Do not miss this opportunity to educate yourself about one of the most cutting-edge Lyme disease treatments available!